Clinical trialNCT05233397RecruitingPhase 2Interventional

ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma

SponsorNationwide Children's HospitalEnrollment30Adamantinomatous CraniopharyngiomaRecurrent Adamantinomatous Craniopharyngioma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

ACTEMRA (tocilizumab) is an IL-6 receptor antagonist used for the treatment of adult Rheumatoid Arthritis as well as Polyarticular (PJIA) and Systemic (SJIA) Juvenile Idiopathic Arthritis. In this Phase II, the drug will be used to treat pediatric patients diagnosed with recurrent Adamantinomatous Craniopharyngioma including patients who have undergone surgery and/or radiation therapy.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Holly Lindsay, MD
Children's Hospital Colorado
Study Chair
clinicaltrials.gov ↗
Maryam Fouladi, MD
Nationwide Children's Hospital
Principal Investigator
clinicaltrials.gov ↗
Todd C Hankinson, MD
Children's Hospital Colorado
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

14 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia

Sydney Children'S Hospital
Randwick, New South Wales, Australia
Recruiting
Queensland Children'S Hospital
South Brisbane, Queensland, Australia
Recruiting
Perth Children'S Hospital
Perth, Western Australia, Australia
Recruiting

Canada

Stollery Children'S Hospital
Edmonton, Alberta, Canada
Recruiting
the Hospital for Sick Children (sickkids)
Toronto, Ontario, Canada
Recruiting
Mcgill University Health Center
Montreal, Quebec, Canada
Recruiting

United States

Children'S Hospital Colorado
Aurora, Colorado, United States
Recruiting
Children'S National Medical Center
Washington D.C., District of Columbia, United States
Recruiting
Nicklaus Children'S Hospital
Miami, Florida, United States
Active, not recruiting
Duke Children'S Hospital
Durham, North Carolina, United States
Recruiting
Cincinnati Children'S Hospital Medical Center
Cincinnati, Ohio, United States
Recruiting
Nationwide Children'S Hospital
Columbus, Ohio, United States
Recruiting
Texas Children'S Hospital
Houston, Texas, United States
Recruiting
Seattle Children'S Hospital
Seattle, Washington, United States
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Tocilizumab →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 16 Dec 2022
Primary completion: 31 Dec 2027
Completion: 31 Dec 2029
Last update posted: 23 Apr 2026
Registered enrollment: 30
Registry id: NCT05233397

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.